Global Gene Therapy for Blood Disorders Market Assessment 2020 -

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on “Global Gene Therapy for Blood Disorders Market Assessment – Revenue (US$ Mn) Forecast Till 2030”

Request for Sample Pages: www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/

According to the latest research by InsightAce Analytic, the global market for gene therapy for blood disorders is estimated to be valued at US$ XX million in 2020 and is expected to reach US$ XX million by 2030, with a remarkable CAGR of XX% from 2020 to 2030.

Gene therapy represents a new approach in human health with the potential to resolve unmet medical needs by using genes to cure, treat, or prevent disease. It fixes defective or mutated genes that require either correction or improved regulation by injecting properly functioning genes into the cells of a patient.

Gene therapy mainly target diseases such as cystic fibrosis, hemophilia, muscular dystrophy, thalassemia, and sickle-cell anemia, as well as a plethora of other monogenic diseases.

Additionally, a substantial amount of gene therapy research and clinical development is also being conducted for cardiovascular disease, neurological disease, and ocular disease, many of which are classified as regenerative gene therapies.

The significant number of ongoing clinical trials related to gene therapy to treat several disorders, strong product pipeline, enhanced research activities by the players, significant prevalence of blood disorders and growing demand for gene therapy to treat blood disorders which have inadequate treatment options are the major growth drivers of the global gene therapy market. For instance, as of November 2020, as per ClinicalTrials.gov, over 3000 human gene therapy interventional clinical trials have been reported globally.

Gene therapy is expected to unite market leaders in the blood disorders treatment arena to research and overcome the commercial challenges and hurdles faced by them while developing gene therapies for sickle cell disease, hemophilia, and β-thalassemia. For instance, in 2018 Sanofi Genzyme, acquired Bioverativ and Ablynx to strengthen its position and offering in the rare blood disorders space.

In January 2020, Sangamo Therapeutics handed over a development of gene therapy, SB-525 to Pfizer for hemophilia A. The candidate is currently under phase 3 of clinical development. The introduction of pipeline drugs to the market in the coming years is expected to generate potential opportunities for the growth of the market during the estimated timeframe.

Request for ToC/Proposal: www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/

Global gene therapy for blood disorders market report covers prominent players such as Biomarin Therapeutics, Spark Therapeutics, Shire, bluebird bio, Inc., CRISPR Therapeutics, Medgenics, OrphageniX, Freeline Therapeutics, Errant Gene Therapeutics, Sangamo Therapeutics, Sigilon Therapeutics, Inc., uniQure, Angiocrine Bioscience, and Sanofi Genzyme.

Curious about this latest version of the report? Obtain Report Details @ www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/

Market Segments
Global Gene Therapy for Blood Disorders Market Revenue (US$ Mn), By Indication, 2020-2030
o Sickle Cell Anemia
o β-thalassemia
o Hemophilia B
o Hemophilia A

Global Gene Therapy for Blood Disorders Market Revenue (US$ Mn), By Mechanism of Action, 2020-2030
o Gene Therapy
o Gene Editing

Global Gene Therapy for Blood Disorders Market Revenue (US$ Mn), By Region, 2020-2030
North America Gene Therapy for Blood Disorders Market Revenue (US$ Mn), By Country, 2020-2030
o U.S.
o Canada

Europe Gene Therapy for Blood Disorders Market Revenue (US$ Mn), By Country, 2020-2030
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe

Asia Pacific Gene Therapy for Blood Disorders Market Revenue (US$ Mn), 2020-2030
Latin America Gene Therapy for Blood Disorders Market Revenue (US$ Mn), 2020-2030
Middle East & Africa Gene Therapy for Blood Disorders Market Revenue (US$ Mn), 2020-2030

Why should buy this report:
To receive a comprehensive analysis of the growth prospects for the global gene therapy for blood disorders market
To receive industry overview and future trends in the gene therapy for blood disorders market
To analyze the major factors (drivers and restraints) influencing the growth of the gene therapy for blood disorders market
To get information on the gene therapy for blood disorders market size value/revenue (US$ Mn) forecast till 2028
To analyze the competitive developments such as major investments, mergers & acquisition in the gene therapy for blood disorders industry

For More Information @ www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/

InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.



Source link